Abstract Inflammatory Bowel Disease (IBD), a chronic nonspecific intestinal inflammatory
disease, is comprised of Ulcerative Colitis (UC) and Crohn's Disease (CD). IBD is closely …

Recent data suggest that inflammatory bowel disease (IBD) patients do not receive
preventive services at the same rate as general medical patients. Patients with IBD often …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

Drug-induced liver injury (DILI) is an important clinical problem, which has received more
attention in recent decades. It can be induced by small chemical molecules, biological …

Risk of complications from specific classes of drugs for inflammatory bowel diseases (IBDs)
can be kept low by respecting contraindications. Patients with IBD frequently develop …

Abstract The Asia–Pacific Working Group on Inflammatory Bowel Disease was established
in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology …

The emergence of tumor necrosis factor-α (TNF-α)-targeted therapies as a key therapeutic
option for patients with rheumatic, digestive, and dermatologic autoimmune diseases has …

Abnormal liver biochemical tests are present in up to 30% of patients with inflammatory
bowel disease (IBD), and therefore become a diagnostic challenge. Liver and biliary tract …

Advances in the treatment of malignant and inflammatory diseases have developed over
time, with increasing use of chemotherapeutic and immunosuppressive agents of a range of …